1. VolitionRx Limited (NYSEAMERICAN:VNRX)
Upside Potential: 1451.32%
On May 15, Cameron Reynolds, President and Group Chief Executive Officer of VolitionRx Limited (NYSEAMERICAN:VNRX), stated that the company made substantial progress across multiple product platforms during the first quarter and following quarter-end developments. Management highlighted the submission for peer review of a clinical manuscript demonstrating high accuracy for the company’s Nu.Q Vet feline prototype assay in detecting lymphoma in cats, representing the third animal species supported by the platform. VolitionRx noted that publication of the study in a peer-reviewed journal is expected to trigger a $5 million contractual milestone payment. The company also believes the feline assay could significantly expand the commercial opportunity for its Nu.Q Vet diagnostic platform within veterinary healthcare markets.
Previously, on April 29, VolitionRx Limited (NYSEAMERICAN:VNRX) announced a major technical milestone involving the successful detection of nucleosomes in capillary blood samples collected from critically ill sepsis patients using the company’s lateral flow prototype technology. The finger-prick testing platform is designed for potential bedside, emergency room, or at-home diagnostic use, similar to rapid COVID-19 or pregnancy tests. Management stated that the study, conducted as part of the SUMMIT program, demonstrated the feasibility of rapidly detecting immune disruptions associated with conditions such as sepsis without requiring centralized laboratory analysis. The advancement could substantially broaden the market opportunity for VolitionRx’s diagnostic technologies beyond traditional clinical laboratory settings.
Founded in 1998 and headquartered in Henderson, VolitionRx Limited (NYSEAMERICAN:VNRX) is a multinational epigenetics company focused on developing cost-effective blood tests for early cancer detection and immune monitoring in both humans and animals. The company’s proprietary technologies analyze nucleosomes circulating in the bloodstream to help identify and monitor serious diseases and health conditions.
While we acknowledge the potential of VNRX as the best penny stock, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VNRX and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 7 Best Heavy Equipment Stocks to Buy as Backlogs Hit Records and 8 Best Rising Tech Stocks to Buy According to Hedge Funds.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
